留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

银杏内酯固体分散体的辅料优选

马颖 吕志阳 狄留庆 李俊松 康安

马颖, 吕志阳, 狄留庆, 李俊松, 康安. 银杏内酯固体分散体的辅料优选[J]. 南京中医药大学学报, 2015, 31(2): 174-178.
引用本文: 马颖, 吕志阳, 狄留庆, 李俊松, 康安. 银杏内酯固体分散体的辅料优选[J]. 南京中医药大学学报, 2015, 31(2): 174-178.
MAYing, LYUZhi-yang, DILiu-qing, LIJun-song, KANGAn. The Choice of Preferred Materials of Ginkgolide Solid Dispersions[J]. Journal of Nanjing University of traditional Chinese Medicine, 2015, 31(2): 174-178.
Citation: MAYing, LYUZhi-yang, DILiu-qing, LIJun-song, KANGAn. The Choice of Preferred Materials of Ginkgolide Solid Dispersions[J]. Journal of Nanjing University of traditional Chinese Medicine, 2015, 31(2): 174-178.

银杏内酯固体分散体的辅料优选

The Choice of Preferred Materials of Ginkgolide Solid Dispersions

  • 摘要: 目的 通过优选最佳辅料及配比来制备银杏内酯固体分散体,以提高银杏内酯体外溶出度。方法 选取聚丙烯酸树脂EPO(Eudragit EPO)、聚维酮K30(PVP K30)分别与银杏内酯以不同配比运用溶剂法制备固体分散体,测定银杏内酯B(ginkgolide B,GB)溶出度,并用差示扫描量热(DSC)、X-射线衍射(X-RD)、扫描电镜(SEM)进行物相表征。结果 以银杏内酯/EPO配比为1∶2、1∶4、1∶6、1∶8制备的固体分散体5 min内GB溶出度分别为65%、68%、70%、71%;银杏内酯/PVP K30在相应配比下制备的固体分散体5 min内GB溶出度分别为40%、50%、66%、70%,而5 min内原料药溶出度为10%。物相鉴别结果表明银杏内酯在2种载体制备的固体分散体中均以无定型状态均匀分散。结论 以银杏内酯/EPO配比为1∶2制备的固体分散体载药量高、溶出效果佳,是制备银杏内酯固体分散体的最佳选择,具有较好的应用前景。

     

  • [1] 陈维军,谢笔钧,胡慰望.银杏萜内酯的化学结构及药理作用研究进展[J].中国药学杂志,1998(9):6-9.
    [2] Chen WJ, Xie BJ, Hu WW. The chemical compositions and medicinal virtues of Ginkgo Biloba Terpene Lactones[J]. Chin Pharm J, 1998(9): 6-9.
    [3] 马琳怡,韩丽妹,张志荣,等.银杏内酯固体分散体的制备和体外特性研究[J].中国中药杂志,2009(11):1368-1372.
    [4] Ma LY, Han LM, Zhang ZR, et al.Preparation and characterization of solid dispersions of ginkgolides[J]. China J Chin Mater Med, 2009(11): 1368-1372.
    [5] 蒋艳荣,张振海,夏海建,等.基于共聚维酮的丹参酮ⅡA固体分散体的研究[J].中国中药杂志,2013(2):174-178.
    [6] Jiang YR, Zhang ZH, Xia HJ, et al. Study on solid dispersion of copovidone-based tanshinone IIA[J]. China J Chin Mater Med, 2013(2): 174-178.
    [7] 〖JP2〗Moustafine RI, Bobyleva VL, Bukhovets AV, et al. Structural transformations during swelling of polycomplex matrices based on countercharged (meth)acrylate copolymers (EudragitR EPO/EudragitR L 100-55)[J]. J Pharm Sci, 2011, 100(3): 874-885.〖JP〗
    [8] Lv H, Wang GJ, Wu XL, et al. Transport characteristics of ginkgolide B by Caco-2 cells and examination of ginkgolide B oral absorption potential using rat in situ intestinal loop method[J]. Int J Pharm, 2008, 351(1/2): 31-35.
    [9] 〖JP2〗Onoue S, Kojo Y, Aoki Y, et al. Physicochemical and pharmacokinetic characterization of amorphous solid dispersion of tranilast with enhanced solubility in gastric fluid and improved oral bioavailability[J]. Drug Metab Pharmacokinet, 2012, 27(4): 379-387.〖JP〗
    [10] Huang SH, Lewis TM, Lummis SC, et al. Mixed antagonistic effects of the ginkgolides at recombinant human rho1 GABAC receptors[J]. Neuropharmacology, 2012, 63(6): 1127-1139.
    [11] Jensen AA, Bergmann ML, Sander T, et al. Ginkgolide X is a potent antagonist of anionic cys-loop receptors with a unique selectivity profile at glycine receptors[J]. J Biol Chem, 2010, 285(13): 10141-10153.
    [12] Van Beek TA. Ginkgolides and bilobalide: Their physical, chromatographic and spectroscopic properties[J]. Bioorg Med Chem, 2005, 13(17): 5001-5012.
    [13] Prasad D, Chauhan H, Atef E. Amorphous stabilization and dissolution enhancement of amorphous ternary solid dispersions: combination of polymers showing drug-polymer interaction for synergistic effects[J]. J Pharm Sci, 2014,103(11):3511-3523.
    [14] 〖JP2〗Wegiel LA, Mauer LJ, Edgar KJ, et al. Mid-infrared spectroscopy as a polymer selection tool for formulating amorphous solid dispersions[J]. J Pharm Pharmacol, 2014, 66(2):244-255.〖JP〗
    [15] Wegiel LA, Mauer LJ, Edgar KJ, et al. Crystallization of amorphous solid dispersions of resveratrol during preparation and storage-Impact of different polymers[J]. J Pharm Sci, 2013, 102(1): 171-184.
  • 加载中
计量
  • 文章访问数:  1061
  • HTML全文浏览量:  3
  • PDF下载量:  1263
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-11-18
  • 修回日期:  2015-01-26
  • 刊出日期:  2015-03-10

目录

    /

    返回文章
    返回